Indian stocks: Visit www.stage2stocks.com →

Scienture Holdings, Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, Scienture Holdings is in Stage 4, the downtrend phase, now in week 5 (since Sep 22, 2026). It closed at $2.77, 95.7% below its 52-week high and below its 200-day average, which is falling.

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. More about the company

$2.77
-4.53% today
$4.5M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SCNX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 15w
S4 25w
S4 42w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 4w → S3 9w → S4 15w → S1 2w → S2 10w → S3 6w → S2 10w → S3 3w → S4 5w → S1 8w → S4 25w → S1 10w → S4 42w → S1 1w → S4 5w → S1 5w → S4 4w current
Total tracked: 165 weeks across 17 stage runs.

SCNX among Pharmaceutical Retailers3rd of 5 by relative strength

All 5 →
Stocks in Pharmaceutical Retailers ranked by relative strength, with stage and one-month change
#StockStageRS1M
1HITIStage 2 · wk 439−2.4%
2PETSStage 4 · wk 3021−23.9%
3SCNXStage 4 · wk 512−61.8%
4POMStage 1 · wk 14+153.8%
5RDGTStage 4 · wk 302−9.7%
vs 52W High
-95.7%
$2.77 lo$65.00 hi
95.7% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 5
1w13w26w
Week 5, early Stage 4 decline
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-70.8%
200 DMA: $9.50 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.13x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-61.8%
3M
-70.0%
6M
-73.5%
YTD
-78.7%
1Y
-78.5%
Scan Membership
Breakout Watch
Latest: 2024-07-02
8 appearances in last 60 days. First seen: 2019-03-25.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 5 · Vol 0.13x
2026-10-21S4
Wk 5 · Vol 0.10x
2026-10-20S4
Wk 5 · Vol 0.09x
2026-10-19S4
Wk 4 · Vol 0.32x
2026-10-16S4
Wk 4 · Vol 0.10x
2026-10-15S4
Wk 4 · Vol 0.22x
2026-10-14S4
Wk 4 · Vol 0.16x
2026-10-13S4
Wk 4 · Vol 2.04x
2026-10-12S4
Wk 3 · Vol 0.17x
2026-10-09S4
Wk 3 · Vol 0.14x
2026-10-08S4
Wk 3 · Vol 0.31x
2026-10-07S4
Wk 3 · Vol 0.48x
Moving averages & range
50 DMA
$7.34
200 DMA
$9.50
52W High
$65.00
52W Low
$2.77
5D Low
$2.77
Resistance levels (recent highs)
20d High
$6.93
60d High
$11.85
120d High
$11.85
250d High
$39.25
Next resistance
+150.0%
to 20d High
ROE
-53.5%
Profit margin 0.0%
Dividend Yield
0.00%
P/B 0.1

Scienture Holdings: quick answers

What stage is Scienture Holdings in?

As of Oct 22, 2026, Scienture Holdings (SCNX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 22, 2026 and is in week 5. What the four stages mean

Is Scienture Holdings in an uptrend?

No. Scienture Holdings is in a Stage 4 downtrend. It trades 70.8% below its 200-day average, which is falling.

How far is Scienture Holdings from its 52-week high?

Scienture Holdings closed at $2.77 on Oct 22, 2026, 95.7% below its 52-week high of $65.00. Its 52-week low is $2.77.

How has Scienture Holdings performed over the past year?

As of Oct 22, 2026, Scienture Holdings is down 78.5% over the past year and down 78.7% so far in 2026.

Which sector and industry is Scienture Holdings in?

Scienture Holdings is in the Pharmaceutical Retailers industry, part of the Health Care sector.

About this companyHealth Care· Pharmaceutical Retailers

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.